Genelux Corp (GNLX)

$2.64 -0.04 (-1.49%)
Market Cap 100.46M
Revenue (ttm) 10,000.00
Net Income (ttm) -29.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -298,700.02%
Debt to Equity Ratio 0.00
Volume 86,900
Avg Vol 245,708
Day's Range N/A - N/A
Shares Out 38.05M
Stochastic %K 78%
Beta 0.20
Analysts Strong Sell
Price Target $19.00

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and periton...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 267 9889
Address:
2625 Townsgate Road, Suite 230, Westlake Village, United States
PortfolioOverture
PortfolioOverture Feb. 20 at 2:13 PM
$GNLX Genelux develops oncolytic virus therapies. Clinical milestones are the primary catalyst. Early-stage risk remains high.
0 · Reply
YieldHarvesting
YieldHarvesting Feb. 17 at 2:46 PM
$GNLX Genelux Corporation is an oncology-focused biotech developing oncolytic virus immunotherapies, with early-stage pipeline assets creating binary clinical catalyst risk.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 10:32 PM
$GNLX RSI: 32.73, MACD: -0.3002 Vol: 0.19, MA20: 2.66, MA50: 3.47 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BounceRaider
BounceRaider Feb. 10 at 1:05 PM
$GNLX is a biotech (Genelux) focused on oncolytic viruses; clinical development is high-risk and capital intensive.
0 · Reply
05ford
05ford Feb. 5 at 4:41 AM
$GNLX boy this thing needs a good shot in the arm.
0 · Reply
cllebye
cllebye Feb. 3 at 2:12 PM
$GNLX Genelux looking past approval to self launch. No competition in 4th line resistant ovarian ca, manageable commercial buildout , and self manufacturing, this startup not playin ...
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jan. 16 at 8:04 PM
$GNLX $3.00 Possible on this break of resistance we have another overnight swing winner... Keep it going🚨🚨
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 11:26 AM
$GNLX Current Stock Price: $2.61 Contracts to trade: $2.5 GNLX Jan 16 2026 Call Entry: $2.34 Exit: $4.10 ROI: 75% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
cllebye
cllebye Jan. 12 at 1:22 PM
$GNLX fully funded through Phase 3 ovarian topline and FDA filing preparations, clear path ahead
1 · Reply
garygb
garygb Jan. 11 at 2:44 PM
$GNLX Holding and adding.My guess is it's bottomed out.
0 · Reply
Latest News on GNLX
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Jan 12, 2026, 4:00 PM EST - 5 weeks ago

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Jan 8, 2026, 9:13 AM EST - 6 weeks ago

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Genelux Corporation Announces Proposed Public Offering of Common Stock

Jan 7, 2026, 4:01 PM EST - 6 weeks ago

Genelux Corporation Announces Proposed Public Offering of Common Stock

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Jan 2, 2026, 8:00 AM EST - 7 weeks ago

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Nov 5, 2025, 4:20 PM EST - 3 months ago

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Aug 7, 2025, 4:20 PM EDT - 7 months ago

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

Jul 7, 2025, 7:00 AM EDT - 8 months ago

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

May 6, 2025, 4:10 PM EDT - 10 months ago

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 28, 2025, 4:10 PM EDT - 11 months ago

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Mar 25, 2025, 8:31 AM EDT - 11 months ago

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Genelux Corporation Announces New Chief Financial Officer

Feb 3, 2025, 6:45 AM EST - 1 year ago

Genelux Corporation Announces New Chief Financial Officer

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Dec 13, 2024, 7:01 AM EST - 1 year ago

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Nov 6, 2024, 4:01 PM EST - 1 year ago

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Oct 31, 2024, 10:59 AM EDT - 1 year ago

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Oct 22, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024, 4:15 PM EDT - 1 year ago

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

May 24, 2024, 8:00 AM EDT - 1 year ago

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

May 23, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

May 9, 2024, 4:25 PM EDT - 1 year ago

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Nov 27, 2023, 7:00 AM EST - 2 years ago

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Nov 14, 2023, 5:50 PM EST - 2 years ago

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

Aug 30, 2023, 1:56 PM EDT - 2 years ago

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Aug 2, 2023, 4:00 PM EDT - 2 years ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Jul 20, 2023, 4:45 PM EDT - 2 years ago

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Jul 11, 2023, 4:12 AM EDT - 2 years ago

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Jul 10, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Jun 29, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Jun 22, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Genelux Corporation Announces $18 Million Private Placement

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces $18 Million Private Placement

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

May 25, 2023, 4:01 PM EDT - 2 years ago

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

Genelux Corporation Announces $33 Million Private Placement

May 15, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces $33 Million Private Placement

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

Mar 26, 2023, 10:50 PM EDT - 3 years ago

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Mar 23, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Genelux IPO prices at bottom of range

Jan 26, 2023, 6:40 AM EST - 3 years ago

Genelux IPO prices at bottom of range

Genelux Corporation Announces Pricing of Initial Public Offering

Jan 25, 2023, 9:00 PM EST - 3 years ago

Genelux Corporation Announces Pricing of Initial Public Offering

IPO Update: Genelux Finalizes $16 Million IPO Plan

Sep 19, 2022, 1:49 PM EDT - 3 years ago

IPO Update: Genelux Finalizes $16 Million IPO Plan

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

Sep 19, 2022, 9:08 AM EDT - 3 years ago

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

PortfolioOverture
PortfolioOverture Feb. 20 at 2:13 PM
$GNLX Genelux develops oncolytic virus therapies. Clinical milestones are the primary catalyst. Early-stage risk remains high.
0 · Reply
YieldHarvesting
YieldHarvesting Feb. 17 at 2:46 PM
$GNLX Genelux Corporation is an oncology-focused biotech developing oncolytic virus immunotherapies, with early-stage pipeline assets creating binary clinical catalyst risk.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 10:32 PM
$GNLX RSI: 32.73, MACD: -0.3002 Vol: 0.19, MA20: 2.66, MA50: 3.47 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BounceRaider
BounceRaider Feb. 10 at 1:05 PM
$GNLX is a biotech (Genelux) focused on oncolytic viruses; clinical development is high-risk and capital intensive.
0 · Reply
05ford
05ford Feb. 5 at 4:41 AM
$GNLX boy this thing needs a good shot in the arm.
0 · Reply
cllebye
cllebye Feb. 3 at 2:12 PM
$GNLX Genelux looking past approval to self launch. No competition in 4th line resistant ovarian ca, manageable commercial buildout , and self manufacturing, this startup not playin ...
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jan. 16 at 8:04 PM
$GNLX $3.00 Possible on this break of resistance we have another overnight swing winner... Keep it going🚨🚨
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 11:26 AM
$GNLX Current Stock Price: $2.61 Contracts to trade: $2.5 GNLX Jan 16 2026 Call Entry: $2.34 Exit: $4.10 ROI: 75% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
cllebye
cllebye Jan. 12 at 1:22 PM
$GNLX fully funded through Phase 3 ovarian topline and FDA filing preparations, clear path ahead
1 · Reply
garygb
garygb Jan. 11 at 2:44 PM
$GNLX Holding and adding.My guess is it's bottomed out.
0 · Reply
PaulThomasTPG
PaulThomasTPG Jan. 9 at 2:22 AM
$FNMA $BBAI Its feels like forever ago, that these were trading as penny stocks! $GNLX running all the way to 250% in 11months, and then plummeting 80% in a month is pretty WILD! https://www.youtube.com/watch?v=8ed505uoqpk
0 · Reply
CSkaugrud
CSkaugrud Jan. 8 at 5:02 PM
$GNLX
0 · Reply
DARKP00L
DARKP00L Jan. 8 at 4:46 PM
$GNLX 11:46 on Jan. 08 2026 Genelux shares are trading lower. The company announced the pricing of a public offering of 6.67 million common shares at a price of $3.00 per share. #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 8 at 2:22 PM
$GNLX 09:15 on Jan. 08 2026 Genelux Prices ~$20M Public Offering Of 6.67M Shares At A Price Of $3/Share #tradeideas
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 8 at 2:08 PM
$GNLX (-10.6% pre) Genelux stock falls after announcing proposed public offering https://ooc.bz/l/89068
0 · Reply
cllebye
cllebye Jan. 8 at 2:03 PM
$GNLX Buy and hold....
1 · Reply
AmaraNic
AmaraNic Jan. 7 at 9:08 PM
$GNLX I’m so disappointed in this one.
0 · Reply
PaulLaurent
PaulLaurent Jan. 6 at 6:57 AM
🚀📈 Top Gainers 📈🚀AH $SKYQ $ALMS $GNLX $MEHA $LOCL
0 · Reply
topstockalerts
topstockalerts Jan. 6 at 3:22 AM
After Hours Top Gainers PT2 $BSCR $VRME $ABOS $GNLX $UFG
0 · Reply
thesaltier1
thesaltier1 Jan. 5 at 9:21 PM
$GNLX I wouldn't touch this until we get a news release on how they plan on raising more capital, I was a long term holder in this but am waiting on the sidelines for now
1 · Reply
justiceforb_85
justiceforb_85 Jan. 5 at 8:04 PM
$GNLX honestly, data did not look bad. More excited though about the P3 in PROC with an update possibly later this year.
0 · Reply
DARKP00L
DARKP00L Jan. 5 at 1:22 PM
$GNLX 08:08 on Jan. 05 2026 Genelux Announces Interim Results From Two Ongoing Trials, Phase 1b/2 SCLC And Phase 2 VIRO-25, Evaluating Systemic Administration Of Olvi-Vec In Patients With Progressive SCLC And NSCLC #tradeideas
0 · Reply